You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,332,289


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,332,289
Title:Method of purifying protein
Abstract: A method for removing contaminant DNA in a sample containing a physiologically active protein, which comprises the following steps: 1) converting the sample containing a physiologically active protein into a neutral aqueous solution of low conductivity; and 2) removing the resulting particles.
Inventor(s): Takeda; Kozo (Tokyo, JP), Ochi; Norimichi (Tokyo, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:10/471,374
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,332,289
Patent Claims:1. A method for removing contaminant DNA in an antibody-containing sample, which comprises the followings steps: 1) applying the antibody-containing sample to affinity chromatography on Protein A or Protein G; 2) eluting the antibody with an acidic aqueous solution of low conductivity having a molarity of 100 mM or less; 3) neutralizing the eluate from step (2) to form particles by addition of a buffer to raise the pH to 4 to 8, wherein the molarity of the neutralized eluate is 100 mM or less; and 4) removing the particles to thereby remove contaminant DNA from the antibody-containing sample.

2. The method according to claim 1, wherein the acidic aqueous solution of low conductivity has a molarity of 50 mM or less.

3. The method according to claim 1, wherein the acidic solution of low conductivity is selected from the group consisting of aqueous solutions of hydrochloric acid, citric acid and acetic acid.

4. The method according to claim 3, wherein the acidic aqueous solution has a pH of 1.5 to 3.9.

5. The method according to claim 1, wherein the contaminant DNA is present at a DNA concentration of 22.5 pg/ml or less in the treated sample containing an antibody.

6. The method according to claim 1, wherein the buffer is an aqueous solution of Tris.

7. The method according to claim 1, wherein the buffer is added to raise the pH to 4.3 to 7.5.

8. The method according to claim 1, wherein the antibody is a humanized monoclonal antibody.

9. The method according to claim 8, wherein the antibody is a humanized anti-IL-6 receptor antibody.

10. The method according to claim 8, wherein the antibody is a humanized anti-HM1.24 antigen monoclonal antibody.

11. The method according to claim 8, wherein the antibody is a humanized anti-parathyroid hormone-related peptide antibody (anti-PTHrP antibody).

12. The method according to claim 8, wherein the antibody is a humanized anti-tissue factor antibody.

13. The method according to claim 1, wherein the particles are removed by filtration through a filter.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.